Bayer prepares to break ECM records for $66bn Monsanto deal
Bayer, the German life sciences company, has clinched an agreement with the board of Monsanto to buy the US company for an enterprise value of $66bn, to be financed with one of the largest rights issues in history.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts